Combined Therapy of Experimental Autoimmune Uveitis by a Dual-Drug Nanocomposite Formulation with Berberine and Dexamethasone
Chang Huang,Zhutian Zhang,Jifeng Gu,Dan Li,Shunxiang Gao,Rong Zhang,Rong Shi,Jianguo Sun
DOI: https://doi.org/10.2147/ijn.s417750
IF: 7.033
2023-08-01
International Journal of Nanomedicine
Abstract:Chang Huang, 1, 2, &ast Zhutian Zhang, 1, 2, &ast Jifeng Gu, 3, &ast Dan Li, 1, 2 Shunxiang Gao, 1, 2 Rong Zhang, 1, 2 Rong Shi, 4 Jianguo Sun 1, 2 1 Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, 200031, People's Republic of China; 2 NHC Key Laboratory of Myopia, Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, 200031, People's Republic of China; 3 Department of Pharmacy, Eye & ENT Hospital, Shanghai Key Laboratory of Bioactive Small Molecules, Fudan University, Shanghai, 200031, People's Republic of China; 4 Science and Technology Experimental Center, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jianguo Sun, Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, People's Republic of China, Email Rong Shi, Science and Technology Experimental Center, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China, Email Purpose: Autoimmune uveitis is a kind of sight-threatening ocular and systemic disorders. Recent treatments on autoimmune uveitis still remain many limitations due to extreme complexity and undetermined pathogenesis. In this study, a novel dual-drug nanocomposite formulation is developed to treat experimental autoimmune uveitis by a combined and sustained therapy method. Methods: The dual-drug nanocomposite formulation is constructed by integrating berberine (BBR)-loaded mesoporous silica nanoparticles (MSNs) into dexamethasone (DEX)-loaded thermogel (@Gel). The @Gel is characterized by transmission electron microscopy, dynamic light scattering, Fourier transform infrared spectrometer and rheometer. The in vitro drug release profile, cytotoxicity and anti-inflammation effectiveness of @Gel on lipopolysaccharide-stimulated human conjunctival epithelial cells are investigated. After the in vivo drug release profile and biosafety of the dual-drug nanocomposite formulation are confirmed, its treatment effectiveness is fully assessed based on the induced experimental autoimmune uveitis (EAU) Lewis rat's model. Results: The dual-drug nanocomposite formulation has good injectability and thermosensitivity, suitable for administration by an intravitreal injection. The @Gel has been found to sustainably release both drugs for up to 4 weeks. The carrier materials have minimal in vitro cytotoxicity and high in vivo biosafety. @Gel presents obviously anti-inflammatory effectiveness in vitro. After administration of @Gel into Lewis rat's eye with EAU by an intravitreal injection, the nanocomposite formulation significantly suppresses inflammatory reaction of autoimmune uveitis via a dual-drug combined and sustained therapy method, compared with the equivalent dose of single-component formulations. Conclusion: @Gel serves as a promising dual-drug nanocomposite formulation for future treatment of autoimmune uveitis. Keywords: nanocomposite formulation, combined and sustained therapy, dexamethasone, berberine, experimental autoimmune uveitis Uveitis, described as the intraocular inflammation of uveal tract (eg, iris, ciliary body, and choroid, etc.), is one of the leading causes of visual impairment among the working-age population. 1 Generally, it can be classified into infectious and non-infectious uveitis, and noninfectious uveitis is related to systemic or idiopathic autoimmune conditions, known as autoimmune uveitis. 2 The estimated prevalence of autoimmune uveitis is 121/100,000 in the United States. 3 Glucocorticoids (eg, dexamethasone (DEX)) remain the primary therapy for autoimmune uveitis for their powerful anti-inflammatory activities. 4 However, long-term DEX treatments may cause serious ocular or systemic adverse effects. 5 As is well known, autoimmune uveitis is a very complicated disease associated with dozens of etiologies and multifactorial pathological mechanisms. 1 Thus, alternative strategies, such as combined therapy targeting different pathophysiological mechanisms, should be explored to treat autoimmune uveitis. Berberine (BBR), a type of isoquinoline alkaloids, is known for its anti-inflammatory, 6 anti-microbial 7 and anti-diabetic 8 properties, with excellent therapeutic effects especially in autoimmune uveitis. 6 In this study, BBR and DEX wer -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology